NGL FINECHEM Financial Statement Analysis
|
||
|
The Revenues of NGL FINECHEM have increased by 21.79% YoY .
The Earnings Per Share (EPS) of NGL FINECHEM has increased by 101.66 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
NGL FINECHEM Last 5 Annual Financial Results
[BOM: 524774|NSE : NGLFINE]
| Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹339 Cr | ₹278 Cr | ₹318 Cr | ₹258 Cr | ₹152 Cr |
| Expenses | ₹285 Cr | ₹243 Cr | ₹249 Cr | ₹178 Cr | ₹132 Cr |
| Operating Profit (Excl OI) | ₹54 Cr | ₹35 Cr | ₹68 Cr | ₹80 Cr | ₹20 Cr |
| Other Income | ₹14 Cr | ₹5.53 Cr | ₹11 Cr | ₹8.02 Cr | ₹3.05 Cr |
| Interest | ₹1.81 Cr | ₹1.83 Cr | ₹1.91 Cr | ₹2.20 Cr | ₹2.63 Cr |
| Depreciation | ₹12 Cr | ₹11 Cr | ₹10 Cr | ₹8.33 Cr | ₹8.11 Cr |
| Profit Before Tax | ₹54 Cr | ₹27 Cr | ₹67 Cr | ₹78 Cr | ₹12 Cr |
| Profit After Tax | ₹41 Cr | ₹20 Cr | ₹50 Cr | ₹57 Cr | ₹8.34 Cr |
| Consolidated Net Profit | ₹41 Cr | ₹20 Cr | ₹50 Cr | ₹57 Cr | ₹8.12 Cr |
| Earnings Per Share (Rs) | ₹66.63 | ₹33.04 | ₹80.68 | ₹91.58 | ₹13.14 |
| PAT Margin (%) | 12.20 | 7.37 | 15.72 | 21.99 | 5.50 |
| ROE(%) | 17.03 | 9.63 | 27.90 | 44.76 | 8.72 |
| ROCE(%) | 20.38 | 11.96 | 33.91 | 53.53 | 11.93 |
| Total Debt/Equity(x) | 0.13 | 0.15 | 0.15 | 0.11 | 0.29 |
Key Financials |
||
| Market Cap | : | ₹ 656.2 Cr |
| Revenue (TTM) | : | ₹ 373.1 Cr |
| Net Profit(TTM) | : | ₹ 32.6 Cr |
| EPS (TTM) | : | ₹ 52.6 |
| P/E (TTM) | : | 20.1 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| NGL FINECHEM | -4.4% | -10.2% | -53.8% |
| SUN PHARMACEUTICAL INDUSTRIES | -1.3% | 4.7% | 3.3% |
| DIVIS LABORATORIES | 1.9% | 1.5% | 41.9% |
| CIPLA | 3.4% | 0.1% | -3.1% |
| TORRENT PHARMACEUTICALS | -4.8% | 1.9% | 20.3% |
| DR REDDYS LABORATORIES | -0.1% | -1% | -11.3% |
| MANKIND PHARMA | -4% | 4% | -1.9% |
| ZYDUS LIFESCIENCES | 0.2% | -2.8% | -15.6% |
| LUPIN | -0.1% | -2% | 19.1% |
NGL FINECHEM Revenues
[BOM: 524774|NSE : NGLFINE]
| Y-o-Y | 21.79 % |
| 5 Yr CAGR | 22.24 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹339 Cr | 21.79 | |
| Mar2023 | ₹278 Cr | -12.42 | |
| Mar2022 | ₹318 Cr | 23.08 | |
| Mar2021 | ₹258 Cr | 70.07 | |
| Mar2020 | ₹152 Cr | - | |
NGL FINECHEM Operating Profit
[BOM: 524774|NSE : NGLFINE]
| Y-o-Y | 53.73 % |
| 5 Yr CAGR | 28.42 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹54 Cr | 53.73 | |
| Mar2023 | ₹35 Cr | -48.74 | |
| Mar2022 | ₹68 Cr | -14.87 | |
| Mar2021 | ₹80 Cr | 305.44 | |
| Mar2020 | ₹20 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 26.25 % |
| 5 Yr CAGR | 5.05 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 15.87% | 26.25 | |
| Mar2023 | 12.57% | -41.48 | |
| Mar2022 | 21.48% | -30.82 | |
| Mar2021 | 31.05% | 138.30 | |
| Mar2020 | 13.03% | - | |
NGL FINECHEM Profit After Tax
[BOM: 524774|NSE : NGLFINE]
| Y-o-Y | 101.67 % |
| 5 Yr CAGR | 50.07 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹41 Cr | 101.67 | |
| Mar2023 | ₹20 Cr | -59.05 | |
| Mar2022 | ₹50 Cr | -11.91 | |
| Mar2021 | ₹57 Cr | 597.03 | |
| Mar2020 | ₹8.12 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 65.54 % |
| 5 Yr CAGR | 22.04 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | 12.2 % | 65.54 | |
| Mar2023 | 7.37 % | -53.12 | |
| Mar2022 | 15.72 % | -28.51 | |
| Mar2021 | 21.99 % | 299.82 | |
| Mar2020 | 5.5 % | - | |
NGL FINECHEM Earnings Per Share (EPS)
[BOM: 524774|NSE : NGLFINE]
| Y-o-Y | 101.66 % |
| 5 Yr CAGR | 50.06 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹67 | 101.66 | |
| Mar2023 | ₹33 | -59.05 | |
| Mar2022 | ₹81 | -11.90 | |
| Mar2021 | ₹92 | 596.96 | |
| Mar2020 | ₹13 | - | |
NGL FINECHEM Return on Capital Employed (ROCE)
[BOM: 524774|NSE : NGLFINE]
| Y-o-Y | 70.40 % |
| 5 Yr CAGR | 14.32 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | 20.38% | 70.40 | |
| Mar2023 | 11.96% | -64.73 | |
| Mar2022 | 33.91% | -36.65 | |
| Mar2021 | 53.53% | 348.70 | |
| Mar2020 | 11.93% | - | |
NGL FINECHEM Share Price vs Sensex
| Current Share Price | : | ₹1,058.4 |
| Current MarketCap | : | ₹ 656.2 Cr |
| Updated EOD on | : | Apr 11,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NGL FINECHEM | -4.4% |
-10.2% |
-53.8% |
| SENSEX | -1.5% |
1.1% |
1.2% |
NGL FINECHEM related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | -2.9% | 1% | -1% |
| BSE HEALTHCARE | -3.5% | 2.1% | 13.7% |
| BSE SMALLCAP | -3.6% | 0.4% | -0.5% |
| BSE MIDSMALLCAP | -5.4% | -1.5% | -2.8% |
No NSE index found
You may also like the below Video Courses
FAQ about NGL FINECHEM Financials
How the annual revenues of NGL FINECHEM have changed ?
The Revenues of NGL FINECHEM have increased by 21.79% YoY .
How the Earnings per Share (EPS) of NGL FINECHEM have changed?
The Earnings Per Share (EPS) of NGL FINECHEM has increased by 101.66 % YoY .
Check out Intrinsic Value of Peers of NGL FINECHEM
Compare Stock Analytics of Peers of NGL FINECHEM
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
